Celltrion stock
Price history
+18.60% over the period1 year: from ₩180,857.14 (November 17, 2025) to ₩214,500.00 (November 16, 2026), +18.60%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | ₩214,500.00 |
| October 30, 2026 | ₩191,600.00 |
| September 30, 2026 | ₩177,700.00 |
| August 31, 2026 | ₩188,900.00 |
| July 31, 2026 | ₩186,700.00 |
| June 30, 2026 | ₩173,300.00 |
| May 29, 2026 | ₩183,714.28 |
| April 30, 2026 | ₩190,952.38 |
| March 31, 2026 | ₩187,809.53 |
| February 27, 2026 | ₩227,142.86 |
| January 30, 2026 | ₩200,000.00 |
| December 30, 2025 | ₩172,380.95 |
| November 28, 2025 | ₩176,761.91 |
| November 17, 2025 | ₩180,857.14 |
At a glance
The company
Biopharmaceutical company developing, producing and selling biosimilars for conditions including rheumatoid arthritis, cancer, inflammatory bowel disease and others
Latest results
Quarter to September 30, 2026 · EPS ₩328.52 (estimate ₩1,653.73)
TickerLandia's take on Celltrion
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 48 vs a median of 77 over its last 10 fiscal years.
- Cheaper than similar companies: trailing 12-month P/E 26 vs 40 (−34%) in a group of 8.
- Strong point: Earnings stability (80/100 in its group). Weak point: Dividend (26/100).
- “Below historical valuation” (South Korea): No. 5 of 7.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−10.27% from the 52-week high
Analysts · 22 analysts
Average target₩278,545.47+29.86% vs. price
Buy 20 · Hold 2 · Sell 0 · Buy
TickerLandia Fingerprint: Celltrion
Compared with similar companies: very high earnings stability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Priceaverage42
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 27.1 48 EV/EBITDA 29.4 62 Price/sales 10.0 54 Price/book 2.42 13 P/E (trailing 12 months) 26.4 35 Profitabilityaverage57
How much it earns on revenue and capital.
Metric Value Position in group Net margin 32.2% 83 Operating margin 31.6% 76 ROE 9.1% 47 Gross margin 61.9% 37 ROA 4.4% 43 Earnings stabilityvery high80
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 9.1% 77 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthhigh73
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +45.00% 75 Earnings growth (year over year) +511.80% 95 Average revenue growth (3 years) +22.15% 48 Financial strengthaverage40
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.21 43 Current ratio 1.36 9 Interest coverage 15.4 56 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.43 54 Dividendlow26
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 0.3% 8 Consecutive dividend years 5 years 57 Payout ratio 10.4% 14 Market momentumstrong73
How the stock has moved compared with the market.
Metric Value Position in group 1-year return +15.17% 62 Distance from 200-day average +12.61% 83 Riskaverage41
How much the price swings.
Metric Value Position in group Volatility (60 days) 30.5% 34 Maximum drawdown (12 months) 32.6% 47
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Celltrion is cheaper than in the past and cheaper than similar companies
On the latest fiscal year's earnings (2025), Celltrion's P/E today is 48.3, below the median of its last 10 fiscal years (77.2; between 38.8 and 115.2 from 2016 to 2025). Celltrion's P/E (trailing 12 months): 26.4, −34% against the median of a group of 8 similar companies (40.2).
Compared with 8 similar companies
| Metric | Celltrion | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 26.4 | Low | |
| Forward P/E | 27.1 | Middle | |
| Operating margin | 31.6% | Middle | |
| ROE | 9.1% | Middle | |
| Debt/equity | 0.21 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Celltrion. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
₩1.39T
Latest quarter · Q2 2026
Net income
₩370.2B
Latest quarter · Q2 2026
Quarterly net margin
26.6%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- ₩49.04T
- P/E
- 26.4
- EPS
- ₩6,840.22
- Volume
- 465.27K
- Daily trading
- €85.22M
- Dividend yield
- 0.33%
- Last ex-dividend on December 29, 2025
How Celltrion is changing
All resultsRevenue grew 17.6% a year on average over the last 5 years
Free cash flow equal to 82% of net income
Shares outstanding up 39.1% in 5 years
Returns
Celltrion returns with dividends
₩1,000 invested in Celltrion 5 years ago, on November 16, 2021, would be worth ₩1,159 today with dividends reinvested: +15.87% in total, +2.99% per year. On price alone it would be ₩1,139 (+13.93%).
| Period | Celltrion | ₩1,000 becomes |
|---|---|---|
| 1 month | +10.57% | ₩1,106 |
| 6 months | +19.29% | ₩1,193 |
| Year to date | +24.43% | ₩1,244 |
| 1 year | +19.09% | ₩1,191 |
| 3 years | +47.83% | ₩1,478 |
| 5 years | +15.87% | ₩1,159 |
| 10 years | +195.38% | ₩2,954 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
Celltrion: technical analysis
Celltrion shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 34.0% below its all-time closing high (₩325,235.47, December 7, 2020).
- Trend
- No clear trend
- RSI (14 sessions)
- 68
- Between 30 and 70
- vs 200-session average
- +12.82%
Support and resistance
Price areas where Celltrion has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price₩214,500.00
- Support₩211,952.38−1.19%4 touches, last on August 12, 2026
- Support₩201,113.09−6.24%4 touches, last on October 21, 2026
- Support₩189,551.90−11.63%10 touches, last on November 4, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 29.9%
- Largest fall in the last year
- −32.65%
Close of November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Celltrion: seasonality
Average monthly price change over 22 years
Over the last 22 years, the strongest month for Celltrion has been May: +12.11% on average, positive in 11 years out of 21. The weakest has been August: −1.77% on average, positive in 10 years out of 22. November, the current month, has been positive in 12 years out of 21 (+4.55% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +3.54% | +1.99% | 11 of 21 |
| February | +4.52% | +2.98% | 13 of 21 |
| March | +2.69% | +5.03% | 13 of 21 |
| April | −1.41% | −0.55% | 10 of 21 |
| May | +12.11% | +1.14% | 11 of 21 |
| June | +7.84% | 0.00% | 10 of 21 |
| July | −0.28% | −4.12% | 8 of 21 |
| August | −1.77% | −0.41% | 10 of 22 |
| September | +0.03% | −3.50% | 9 of 22 |
| October | −1.20% | −0.84% | 10 of 22 |
| November | +4.55% | +3.24% | 12 of 21 |
| December | +4.82% | +2.37% | 12 of 21 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Celltrion and its competitors
Patients in roughly 100 countries receive Celltrion's medicines, and the United States and Europe are among its main sales territories. The Incheon-based group develops, manufactures and sells biosimilars, which are copies of biologic drugs, for autoimmune diseases, cancers, osteoporosis, eye disorders and asthma. Its marketed brands include Remsima, Truxima, Herzuma, Yuflyma, Vegzelma, Omlyclo, Eydenzelt, Steqeyma, Stoboclo, Osenvelt, Avtozma and Zymfentra, along with Regkirona for COVID-19.
- Headquarters
- Incheon, South Korea
- Employees
- 2,956
- Founded
- 2002
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Celltrion068270 | $36.68B | 31.6% | 26.4 | +19.29% |
| Samsung Biologics207940 | $49.13B | 45.5% | 33.4 | +0.28% |
| WuXi Biologics (Cayman)2269 | $24.52B | 32.4% | 35.1 | +38.78% |
| CSLCSL | $65.65B | 26.8% | — | +106.74% |
| Innovent Biologics1801 | $18.84B | 7.4% | 111.5 | +2.32% |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | $13.65B | -0.2% | — | +0.78% |
Same industry or related industries, similar size. Compare Celltrion with its competitors · Full profile
